title: Nanotechnology Applications for Glaucoma.
abstract: Glaucoma is the second leading cause of blindness worldwide, and the antiglaucoma treatments currently available suffer from various complications. Nanotechnology-based treatments show a great deal of promise in overcoming these complications and form the basis for next-generation glaucoma treatment strategies, with the help of applications such as controlled release, targeted delivery, increased bioavailability, diffusion limitations, and biocompatibility. Significant progress has been made in nanomedicine in the efficiency of antiglaucoma medications, nanofabrication systems such as microelectromechanical systems that remove the limitations of nanodevices, and tissue regeneration vesicles for developing glaucoma treatments not based on intraocular pressure. With the use of these advanced technologies, the prevention of glaucoma-induced blindness will be possible in the near future. Herein, we reviewed the recent advances in nanotechnology-based treatment strategies for glaucoma.
authors.affiliation: From the Chemical and Materials Engineering and Ingenuity Lab, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Sibel
authors.initials: S
authors.lastname: Cetinel
authors.forename: Carlo
authors.initials: C
authors.lastname: Montemagno
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D017889:Exfoliation Syndrome / Q000188:drug therapy; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D020327:Glaucoma Drainage Implants; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D050997:Nanomedicine / Q000379:methods*; D018696:Neuroprotective Agents / Q000008:administration & dosage; D009798:Ocular Hypertension / Q000188:drug therapy
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D018696:Neuroprotective Agents